摘要
受体酪氨酸激酶(RTK)家族是由不同的细胞表面糖蛋白组成。这些酶参与和调节重要的过程,如细胞增殖,极性,分化,细胞与细胞的相互作用,信号,和细胞的生存。失调的RTKs将导致不同类型肿瘤的发展。据报道,在不同的癌症中有超过三十种RTK出现反常。由于其关键作用,特异性靶向与RTK是治疗恶性肿瘤的可靠方法。有针对性的细胞和分子疗法(个性化医学)被称为新疗法,它可以防止肿瘤细胞的增殖和侵袭和干扰对肿瘤生存和生长必不可少的分子。特异性单克隆抗体靶向于RTK对治疗恶性肿瘤以及自身免疫性疾病是十分有趣的。越来越多的单克隆抗体被批准表明这些治疗方法应用的增多以及越来越受到人们的关注。由于高的特异性, mAbs是靶向于在肿瘤细胞表面表达的RTKs的最有前景的物质。本文回顾了单克隆抗体靶向于oncogenic RTKs以治疗癌症的最新研究进展。
关键词: 癌症,单克隆抗体,受体酪氨酸激酶,靶向治疗。
图形摘要
Current Drug Targets
Title:Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Volume: 17 Issue: 14
Author(s): Mahdi Shabani and Mohammad Hojjat-Farsangi
Affiliation:
关键词: 癌症,单克隆抗体,受体酪氨酸激酶,靶向治疗。
摘要: Receptor tyrosine kinases (RTKs) family is comprised of different cell surface glycoproteins. These enzymes participate in and regulate vital processes such as cell proliferation, polarity, differentiation, cell to cell interactions, signaling, and cell survival. Dysregulation of RTKs contributes to the development of different types of tumors. RTKs deregulation in different types of cancer has been reported for more than 30 RTKs. Due to their critical roles, the specific targeting of RTKs in malignancies is a promising approach. Targeted cellular and molecular therapies (personalized medicine) have been known as new types of therapeutics, which prevent tumor cell proliferation and invasion by interfering with molecules essential for tumor growth and survival. Specific targeting of RTKs using monoclonal antibodies (mAbs) in malignancies as well as in autoimmune disorders is of great interest. The growing number of mAbs approved by the authorities implies on the increasing attentions and applications of these therapeutic tools. Due to the high specificity, mAbs are the most promising substances that target RTKs expressed on the tumor cell surface. In this communication, we review the recent progresses in the development of mAbs targeting oncogenic RTKs for cancer treatment.
Export Options
About this article
Cite this article as:
Mahdi Shabani and Mohammad Hojjat-Farsangi , Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy, Current Drug Targets 2016; 17 (14) . https://dx.doi.org/10.2174/1389450116666151001104133
DOI https://dx.doi.org/10.2174/1389450116666151001104133 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity
Current Cancer Drug Targets Vascular Effects of Phytoestrogens and Alternative Menopausal Hormone Therapy in Cardiovascular Disease
Mini-Reviews in Medicinal Chemistry Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
Current Topics in Medicinal Chemistry Computational Simulations of the Immune System for Personalized Medicine: State of the Art and Challenges
Current Pharmacogenomics and Personalized Medicine Computational and Synthetic Biology Approaches for the Biosynthesis of Antiviral and Anticancer Terpenoids from <i>Bacillus subtilis</i>
Medicinal Chemistry Editorial (Mini-Thematic Issue: Morphological and Molecular Backgrounds for Personalized Therapies in Genitourinary Cancers)
Current Drug Targets SELDI Protein Chip Technology for the Detection of Serum Biomarkers for Liver Disease
Protein & Peptide Letters Therapeutic Targeting of Apoptotic Pathways in Cancer
Current Drug Targets The Emerging Role of EMT-related lncRNAs in Therapy Resistance and their Applications as Biomarkers
Current Medicinal Chemistry Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches
Current Stem Cell Research & Therapy Targeting Tumor Lymphangiogenesis: An Update
Current Medicinal Chemistry Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Mucoadhesive Vaginal Drug Delivery Systems
Recent Patents on Drug Delivery & Formulation Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Temporal Expression of miRNAs in Laser Capture Microdissected Palate Medial Edge Epithelium from Tgfβ3<sup>-/-</sup> Mouse Fetuses
MicroRNA Anti-Angiogenesis in the Treatment of Genito-Urinary Cancers: Last Updates
Current Angiogenesis (Discontinued) DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design Compound Ranking Based on a New Mathematical Measure of Effectiveness Using Time Course Data from Cell-Based Assays
Combinatorial Chemistry & High Throughput Screening